One of the goals of anti-vascular endothelial growth factor (VEGF) injections as a treatment of neovascular (wet) age-related macular degeneration is to reduce retinal fluid. It is an elusive goal for some patients. The authors of a literature review published recently in Ophthalmology Retina said that their analysis showed that nearly half of all treated patients have persistent retinal fluid and that almost 1 in 5 never attain complete fluid retention. It is also turning out to be a more complicated story than that a drier retina is a healthier one. Some evidence suggests that subretinal fluid may be neutral or even have some benefits for visual acuity.

Results presented today at the American Society of Retina Specialists annual meeting add another episode to the evolving retinal fl

See Full Page